Comparison of the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiac Fibroblast Properties
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262010098 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Claire Baufays und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pôle de Recherche Cardiovasculaire, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, 1200 Brussels, Belgium. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Fibroblasts, Myocardium. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FRS-FNRS, Action de Recherche Concertée de la Communauté Wallonie-Bruxelles.
Abstract (Originalsprache)
Recent clinical trials have shown significant cardioprotective effects of antidiabetic sodium-glucose cotransporter 2 inhibitors (SGLT2i), including canagliflozin, empagliflozin, and dapagliflozin. These drugs significantly reduce hospitalizations for heart failure with reduced and preserved ejection fraction in both diabetic and non-diabetic patients. Yet, the mechanisms underlying their protective effects, beyond their glucose-lowering properties, remain poorly understood. This study aimed to elucidate the direct effects of SGLT2i on cardiac fibroblasts, key mediators of myocardial fibrosis, ventricular remodeling, and heart failure. Using primary human cardiac fibroblast cultures, we compared the impact of canagliflozin, empagliflozin, and dapagliflozin on fibroblast properties. All three inhibitors significantly prevented myofibroblast differentiation. Notably, only canagliflozin significantly reduced fibroblast proliferation and migration. While all SGLT2i increased AMP-activated protein kinase (AMPK) phosphorylation, their effects on myodifferentiation were AMPK-independent. In contrast, the effect of canagliflozin on migration was partially dependent on AMPK, as demonstrated using the AMPK inhibitor BAY-3827. These findings reveal distinct cellular effects of individual SGLT2i on cardiac fibroblasts, suggesting heterogeneous potential to modulate extracellular matrix remodeling. Among them, canagliflozin may be more potent in preventing myocardial fibrosis in the context of heart failure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pôle de Recherche Cardiovasculaire, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, 1200 Brussels, Belgium.
- Division of Cardiology, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium.
- Division of Cardiovascular Intensive Care, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium.
ORCID-Profile: Luc Bertrand, Alice Marino
Förderung
- FRS-FNRS
- Action de Recherche Concertée de la Communauté Wallonie-Bruxelles
Zitieren
APA
Baufays, C., Cumps, J., Dufeys, C., Ginion, A., Bertrand, L., Horman, S., Beauloye, C., & Marino, A. (2025). Comparison of the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiac Fibroblast Properties. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262010098
Vancouver
Baufays C, Cumps J, Dufeys C, Ginion A, Bertrand L, Horman S, et al. Comparison of the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiac Fibroblast Properties. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262010098
BibTeX
@article{Baufays2025,
author = {Baufays, Claire and Cumps, Julien and Dufeys, Cécile and Ginion, Audrey and Bertrand, Luc and Horman, Sandrine and Beauloye, Christophe and Marino, Alice},
title = {Comparison of the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiac Fibroblast Properties},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262010098}
}
EUVIMED